Related Experiment Video
Updated: May 12, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study
Maria Pia Amato1, Lorenzo Razzolini, Benedetta Goretti
1Department of Neurology, University of Florence, Italy. mariapia.amato@unifi.it
Neurology
|April 12, 2013
Summary
Cognitive reserve (CR) helps maintain cognitive function in multiple sclerosis (MS) patients, but this protective effect diminishes as brain atrophy progresses. Early interventions targeting intellectual enhancement are crucial for managing MS cognitive decline.
Area of Science:
- Neuroscience
- Neurology
- Cognitive Science
Background:
- Multiple Sclerosis (MS) is a chronic neurological disease affecting cognitive function.
- Cognitive Reserve (CR) hypothesis suggests that higher reserves can compensate for brain pathology.
- Understanding the interplay between CR, brain atrophy, and cognitive efficiency in MS is crucial.
Purpose of the Study:
- To investigate the role of Cognitive Reserve (CR) in mitigating cognitive decline in relapsing-remitting MS.
- To examine the interaction between CR, brain atrophy, and cognitive performance.
- To identify predictors of cognitive deterioration in MS patients over time.
Main Methods:
- Calculated a Cognitive Reserve Index (CRI) based on education, leisure activities, and IQ.
- Assessed brain atrophy using MRI quantitative parameters (normalized total brain volume, normalized cortical volume).
- Measured cognitive function with Rao's Brief Repeatable Battery.
Main Results:
- Higher CR at baseline correlated with better cognitive performance, independent of brain atrophy.
- An interaction between CRI and normalized cortical volume predicted enhanced verbal memory and processing speed.
- At follow-up, progressive cortical atrophy and older age predicted cognitive decline.
Conclusions:
- Higher CR may initially compensate for brain pathology in MS patients.
- This compensatory mechanism may fail as MS-related brain damage progresses.
- Therapeutic strategies focusing on intellectual enhancement should target early disease stages.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...